Regeneron Pharmaceuticals Inc. (REGN)

NASDAQ: REGN · USD

$813

-2.77 (-0.3%)· Recorded snapshot

Dự phòng tiếng AnhVI

Hiển thị bản gốc tiếng Anh trong khi đang dịch

Báo cáo này chưa được dịch. Hãy làm mới sau vài phút khi hàng đợi dịch xử lý xong.

StockMarketAgent Research · Analyzed 2026-05-10

Our latest published analysis: REGN rated Strong Buy

Regeneron Pharmaceuticals Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$1,210 / share

Potential value

$1,505 / share

Upside to FV

+69.2%

from $813

Moat

9/10

Wide

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$74.9B
Revenue (ttm)	15.5B
Net income (ttm)	4.3B
EPS (ttm)	$40.4
Shares out	99.9M
P/E (trailing)	20.1x
P/E (forward)	13.3x
Dividend	$3.76 (0.46%)
Volume	353,597
Beta	0.15

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 15.5B
Net income (ttm): 4.3B
EPS (ttm): $40.4
P/E (trailing): 20.1x
P/E (forward): 13.3x
Market cap: $74.9B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	—	$12.17B	$13.12B	$14.20B	$14.34B	+5.6%
Gross profit	—	$10.61B	$11.30B	$12.23B	$12.24B	+4.9%
Operating income	—	$4.92B	$4.27B	$4.84B	$5.27B	+2.4%
Net income	—	$4.34B	$3.95B	$4.41B	$4.50B	+1.3%
EPS (diluted)	$71.97	$38.22	$34.77	$38.34	$41.48	-12.9%
EBITDA	—	$5.26B	$4.69B	$5.32B	$5.82B	+3.4%
R&D	—	$3.85B	$4.63B	$5.23B	$5.85B	+15.0%
SG&A	—	$2.12B	$2.63B	$2.95B	$2.70B	+8.5%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	Bán
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	Bán
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	Mua mạnh
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	Bán
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	Giảm
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	Giảm

Base and Bull scenarios

Bull20%

Price target

$1,505.07

+110.5% from spot

Dupixent dominates the immunology space longer than anticipated, and high-dose Eylea proves impenetrable to biosimilar erosion. Operating leverage drives margins past 35%, yielding an intrinsic value of $1,505.

Dupixent extends dominance in multi-indication immunology.
High-dose Eylea seamlessly defends franchise against biosimilars.
Operating margins expand beyond 35% on operating leverage.

Base60%

Price target

$1,209.72

+69.2% from spot

Our baseline assumes a successful transition from legacy assets to next-gen indications. Margins normalize to 30% as peak R&D spending subsides, anchoring fair value at $1,210 and bridging the gap from overly pessimistic internal valuation cross-checks.

Steady Dupixent growth offsets gradual Eylea base erosion.
R&D spend normalizes, returning operating margins to 30%.
Terminal growth rate of 3% with a terminal multiple of 18x.

Sensitivity: Ke × terminal growth

Ke ↓ / g →	2.0%	2.5%	3.0%	3.5%	4.0%
5.6%	$1,545	$1,793	$2,117	$2,117	$2,117
6.6%	$1,210	$1,357	$1,545	$1,793	$2,117
7.6%	$994	$1,091	$1,210	$1,357	$1,545
8.6%	$844	$913	$994	$1,091	$1,210
9.6%	$733	$784	$844	$913	$994

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E13.3

P25 n/aP50 n/aP75 n/a

Trailing P/E17.5

P25 n/aP50 n/aP75 n/a

ROE14

P25 n/aP50 n/aP75 n/a

ROIC13.5

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All REGN indicators

Market & fundamental data

Available fields

284

Groups with data

Currency

USD

Showing 284 of 284 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000872589
Company name	Regeneron Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	75886F107
Earnings date	2026-10-30
Earnings time	bmo
Employees	15,343
Employees change	185
Employees growth	1.22%
Enterprise value	$66.1B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1988
In index	SP500, NASDAQ100
Industry	Biotechnology
IPO date	1991-04-02
Is primary listing	Yes
Is SPAC	No
ISIN number	US75886F1075
Last 10-K release date	2026-02-04
Last earnings date	2026-07-30
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$81.2B
Market cap category	Large-Cap
Next earnings date	2026-10-30
Options	Yes
Price	$813.33
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	REGN
U.S. state	New York
Website	https://www.regeneron.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	17.29x
Average P/E ratio (10Y)	21.32x
Average P/E ratio (3Y)	19.22x
Average P/E ratio (5Y)	16.94x
Earnings yield	4.97%
EV/Earnings	15.38x
EV/EBIT	15.95x
EV/EBITDA	14.16x
EV/FCF	17.71x
EV/Sales	4.29x
FCF / EV yield	5.65%
FCF yield	4.6%
Forward EV/Sales	3.51x
Forward P/E	12.35x
Forward P/S	4.31x
Graham number	536.2672
Graham upside	-34.45%
Lynch fair value	$202.17
Lynch upside	-75.29%
P/(FCF - SBC) ratio	29.45x
P/(OCF - SBC) ratio	22.11x
P/B ratio	2.58x
P/E ratio	20.12x
P/FCF ratio	21.72x
P/OCF ratio	17.45x
P/S ratio	5.26x
PEG ratio	1.04x
Price / tangible book value	2.69x
Price/EBITDA ratio	17.37x
Sector forward P/E	23.53x
Sector P/E	51.01x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	26.87%
EBITDA margin	30.27%
Effective tax rate	16.21%
FCF margin	24.21%
Gross margin	44.46%
Operating margin	26.87%
Pretax margin	33.25%
Profit margin	27.86%
Profit per employee	$282,129
Profitable quarters	58
Profitable years	14
Revenue per employee	$1M
ROA	6.53%
ROA (5Y)	11.91%
ROCE	11.53%
ROE	14.04%
ROE (5Y)	24.44%
ROIC	13.5%
ROIC (5Y)	28.16%
SBC / revenue	6.35%
Tax / revenue	5.39%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	1.92%
EPS growth (Q)	-4.53%
EPS growth (QoQ)	81.19%
EPS growth 10Y	20.22%
EPS growth 3Y	2.25%
EPS growth 5Y	-6.1%
EPS growth years	2
FCF growth	-2.42%
FCF growth (Q)	-38.1%
FCF growth (QoQ)	-32.48%
FCF growth 3Y	-3.26%
FCF growth 5Y	17.3%
Gross profit growth	2.61%
Gross profit growth (Q)	20.82%
Gross profit growth 3Y	0.47%
Gross profit growth 5Y	-2.58%
Net income growth	-2.91%
Net income growth (Q)	-6.81%
Net income growth (QoQ)	78.34%
Net income growth 3Y	0.23%
Net income growth 5Y	-6.95%
Net income growth years	2
OCF growth	-1.31%
OCF growth (Q)	-28.96%
OCF growth (QoQ)	-24.65%
OCF growth 10Y	11.2%
OCF growth 3Y	-0.41%
OCF growth 5Y	15.56%
Operating income growth	5.49%
Operating income growth (Q)	30.38%
Operating income growth 3Y	-1.89%
Operating income growth 5Y	-8.98%
Revenue growth	9.29%
Revenue growth (Q)	16.74%
Revenue growth (QoQ)	19.01%
Revenue growth 10Y	12.82%
Revenue growth 3Y	7.03%
Revenue growth 5Y	4.64%
Revenue growth quarters	5
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-920.9M
Depreciation and amortization	$528.6M
EBIT	$4.2B
EBITDA	$4.7B
EPS	$40.43
FCF per share	$37.66
Financing cash flow	$-3.5B
Free cash flow	$3.8B
Free cash flow minus SBC	$2.8B
Gross profit	$6.9B
Income taxes	$837.3M
Investing cash flow	$-704.2M
Net cash flow	$450.4M
Net income	$4.3B
Operating cash flow minus SBC	$3.7B
Operating income	$4.2B
Revenue	$15.5B
Stock-based compensation	$986.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	6.47
Book value per share	$316.11
Debt / EBITDA	0.57
Debt / equity	0.09
Debt / FCF	0.72
Interest coverage	75.34
Long-term assets	$23.3B
Long-term liabilities	$4.5B
Net cash (debt)	$15.1B
Net cash / market cap	18.5%
Net cash growth	1.98%
Net debt / EBITDA	-3.21
Net debt / equity	-0.48
Net debt / FCF	-4.02
Piotroski F-Score	5
Property, plant and equipment	$5.5B
Shareholders' equity	$31.7B
Tangible book value	$30.4B
Tangible book value per share	$303.05
Total assets	$41.7B
Total cash	$8B
Total debt	$2.7B
Total liabilities	$10B
WACC	4.99%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.39
Current assets	$18.4B
Current liabilities	$5.5B
Current ratio	3.34
Inventory turnover	2.74
Net working capital	$5.6B
Quick ratio	2.63
Working capital	$12.9B
Working capital turnover	1.19

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	4.76%
Dividend growth	0%
Dividend growth years	0
Dividend payment date	2026-08-31
Dividend payment years	2
Dividend payout frequency	Quarterly
Dividend per share	$3.76
Dividend yield	0.46%
Ex-dividend date	2026-08-18
FCF payout ratio	9.83%
Last dividend	$0.94
Payout ratio	9.15%
Shareholder yield	5.22%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	121.54%
10Y return CAGR	8.38%
10Y total return	123.63%
150-day SMA	$727.19
15Y price change	1,334.34%
15Y return CAGR	19.5%
15Y total return	1,347.88%
1D price change	-0.34%
1M price change	2.71%
1M total return	2.71%
1W price change	0.24%
1W total return	0.24%
1Y price change	38.29%
1Y return CAGR	39.03%
1Y total return	39%
20-day SMA	$774.86
200-day SMA	$736.35
20Y price change	4,016.99%
20Y return CAGR	20.49%
20Y total return	4,055.84%
3M price change	21.32%
3M total return	21.46%
3Y price change	4.41%
3Y return CAGR	1.77%
3Y total return	5.4%
50-day SMA	$791.64
50-day SMA vs 200-day SMA	50over200
52-week high	$859.34
52-week high date	2026-09-03
52-week low	$591.52
52-week low date	2026-06-02
5Y price change	37.28%
5Y return CAGR	6.74%
5Y total return	38.58%
6M price change	8.73%
6M total return	9.02%
All-time high	$1,211.20
All-time high date	2024-08-27
All-time low	$3.00
All-time low date	1994-12-29
Average true range (ATR)	$20.49
Average volume	633.1K
Beta (1Y)	-0.01
Beta (2Y)	0.54
Beta (5Y)	0.15
Change from 52-week high	-5.35%
Change from 52-week low	37.5%
Change from all-time high	-33.17%
Change from all-time low	26,880%
Change from open	1.09%
Day's gap	-1.42%
Dollar volume	$287.6M
High price	$820.00
Low price	$804.45
Monthly RSI	55.44
Open price	$804.54
Position in 52-week range	57.11%
Premarket change	-0.32%
Premarket close	$816.10
Premarket price	$813.51
Premarket volume	285
Previous close	$816.10
Price vs 150-day SMA	11.3%
Price vs 20-day SMA	4.46%
Price vs 200-day SMA	9.92%
Price vs 50-day SMA	2.24%
Relative volume	0.56
RSI	58.28
Sharpe ratio	1.04
Sharpe ratio (3Y)	0.06
Sharpe ratio (5Y)	0.27
Sortino ratio	1.83
Sortino ratio (3Y)	0.26
Sortino ratio (5Y)	0.57
Volume	353.6K
Weekly RSI	58.47
YTD price change	4.86%
YTD total return	5.27%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	95.8M
Float percentage	95.99%
Shares change (QoQ)	-1.58%
Shares change (YoY)	-4.76%
Shares held by insiders	3.83%
Shares held by institutions	93.74%
Shares outstanding	99.9M
Short % of float	2.24%
Short % of shares	2.15%
Short ratio	2.9 days

Deeper analysis on REGN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this REGN report

What is the latest published REGN stock rating?

Regeneron Pharmaceuticals Inc. is shown with Strong Buy in the latest published report, analyzed 2026-05-10. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full REGN analysis?

The full latest published report, analyzed 2026-05-10, lives at /stocks/REGN/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for REGN?

The latest published report analyzed 2026-05-10 gives REGN a fair value of USD 1,210 and a potential value of USD 1,505. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the REGN page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-10). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

Strong BuyREGN · Fair value $1,210+69.2%

Read full analysis →

Regeneron Pharmaceuticals Inc. (REGN)

Our latest published analysis: REGN rated Strong Buy

Price

Financial snapshot

Fair-value bridge

Latest news · REGN

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All REGN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on REGN

Frequently asked questions

Lịch sử xếp hạng

Category	Score	Reading
Valuation	9.5
Management	6.9
Balance Sheet	8.5
Profitability	6.5
Revenue Growth	7.5
Risk Assessment	9.0
Competitive Moat	9.0
Earnings Quality	6.0
Capital Efficiency	6.5